1 / 64

Activity Goals

Activity Goals. Upper Gastrointestinal Cancer in the United States: 2012. Incidence: 1930 -1975. Incidence of Stomach Cancer, United States. Gastric Cancer Mortality: Regional Differences. Gastric Cancer: Pathology. Gastric Cancer: Single-Agent Chemotherapy.

whitney-soto
Download Presentation

Activity Goals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Activity Goals

  2. Upper Gastrointestinal Cancer in the United States: 2012

  3. Incidence: 1930 -1975

  4. Incidence of Stomach Cancer, United States

  5. Gastric Cancer Mortality: Regional Differences

  6. Gastric Cancer: Pathology

  7. Gastric Cancer: Single-Agent Chemotherapy

  8. FAMtx vs ELF vs 5-FU + Cisplatin in Advanced Gastric Cancer

  9. Gastric Cancer: Chemotherapy vs Supportive Care

  10. ECF vs FAMtx in Advanced Esophagogastric Cancer

  11. OS: Comparing 5-FU With Capecitabine

  12. OS: Comparing Oxaliplatin With Cisplatin

  13. CALGB 80403/ECOG 1206: Schema

  14. CALGB 80403/ECOG 1206: Results

  15. CALGB 80403/ECOG 1206: Toxicity

  16. ToGA: A Randomized, Open-Label, Multicenter Phase 3 Study

  17. ToGA Primary End Point: OS

  18. Efficacy -- OS by Subgroup Analysis

  19. OS by IHC 2+/3+/FISH2+ (Post hoc Exploratory Analysis)

  20. LOGiC: CapeOx +/- Lapatinib in First-line ErbB2-Amplified Gastric Cancer

  21. TYTAN Trial: Phase 3 in Second-line Gastric Cancer

  22. TYTAN: Results

  23. T-DM1 Structure

  24. Phase 3 Study of T-DM1 vs Taxane in Patients With HER2 Gastric Cancer

  25. EGFR Signal Transduction

  26. Single-Agent Cetuximab in Metastatic Esophagogastric Adenocarcinoma

  27. REAL-3 -- Primary End Point: OS

  28. EXPAND: Phase 3 Trial Cape-C +/- Cetuximab

  29. MET Amplification as a Predictor of Drug Sensitivity in Gastroesophageal Adenocarcinoma

  30. Rilotumumab: An Investigational, Fully Human Monoclonal Antibody

  31. Phase 2 Study of Rilotumumab/ECX in Gastric Cancer

  32. Clinical Efficacy in the ITT Population

  33. Improves PFS and OS in Patients With MET-High Disease

  34. Phase 3 Trials With Antibodies to c-Met

  35. Survival After Gastric Cancer Resection and VEGF Expression (IHC)

  36. AVAGAST: Bevacizumab in Advanced Gastric Cancer

  37. AVAGAST Study Results

  38. AVAGAST: OS by Region

  39. Role of the VEGF Pathway in Tumor Growth

  40. DC101 Inhibits Tumor Growth

  41. Ramucirumab: Phase 1 Summary

  42. REGARD Study Design

  43. REGARD: OS

  44. RAINBOW: Phase 3 Study of Paclitaxel +/- Ramucirumab in Second-line Gastric Cancer

  45. Abbreviations

  46. Abbreviations (cont)

  47. Abbreviations (cont)

More Related